{"id":19388,"date":"2026-05-17T03:21:49","date_gmt":"2026-05-17T03:21:49","guid":{"rendered":"https:\/\/www.europesays.com\/korea\/19388\/"},"modified":"2026-05-17T03:21:49","modified_gmt":"2026-05-17T03:21:49","slug":"samsung-biologics-pays-280m-for-u-s-drug-manufacturing-facility-biotech","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/korea\/19388\/","title":{"rendered":"Samsung Biologics Pays $280M For U.S. Drug Manufacturing Facility- Biotech"},"content":{"rendered":"

Marking a significant expansion of the company\u2019s global footprint and long-term commitment to the U.S. market, Samsung Biologics America (SBA) has entered into an agreement with GSK to acquire 100% of Human Genome Sciences located in Rockville, Maryland for $280 million. SBA is a wholly owned U.S. subsidiary of South Korea-based contract development and manufacturing organization (CDMO) Samsung Biologics<\/a>. The move establishes Samsung Biologics\u2019 first U.S.-based manufacturing site.<\/p>\n

\"SamsungThe Rockville, MD facility is located at the center of a key U.S. bio-cluster and encompasses two cGMP manufacturing plants. (Source: Samsung Biologics)<\/p>\n

The Rockville facility encompasses two Current Good Manufacturing Practices (cGMP) manufacturing plants with a combined 60,000 liters of drug substance capacity, supporting both clinical and commercial production from small to large scale. Existing products will continue to be manufactured at the site, and Samsung Biologics plans to make additional investments to expand the site\u2019s capacity and upgrade technology to further support a more resilient U.S. supply chain for critical biologic medicines.<\/p>\n

\u201cThis landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics,\u201d said John Rim, CEO and President of Samsung Biologics. \u201cThis marks an important step forward in our mission to achieve a better life through biomedicines, and we look forward to building on the legacy of this facility as we welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact.\u201d<\/p>\n

Under the terms of the agreement, with closing anticipated in early 2026, Samsung Biologics will retain more than 500 employees at the site to ensure operational continuity and stability. By integrating this facility into its global network, Samsung Biologics will provide clients with flexible, multi-site options in both the U.S. and Korea to ensure that live-saving therapeutics are reliably available to American patients.<\/p>\n

With 785,000 liters of capacity across five plants<\/a>, Samsung Biologics continues to advance its diversified portfolio spanning monoclonal antibodies, antibody-drug conjugates (ADCs), mRNA, organoid-based services, and next-generation therapies.<\/p>\n

\u201cToday\u2019s agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on U.S. soil for U.S. patients and further build GSK\u2019s supply chain resilience,\u201d said Regis Simard, President, Global Supply Chain, GSK<\/a>. \u201cAlong with GSK\u2019s recent commitment to invest $30 billion in R&D and manufacturing in the U.S. over the next five years, this deal enables us to further focus on building the agility, capacity and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines. I am confident in a positive partnership and future for the Rockville site.\u201d\u202f\u00a0<\/p>\n

Samsung Biologics also operates commercial offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region.<\/p>\n

Check out all the latest news\u00a0related to Maryland economic development, corporate relocation, corporate expansion and site selection.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Marking a significant expansion of the company\u2019s global footprint and long-term commitment to the U.S. market, Samsung Biologics…\n","protected":false},"author":2,"featured_media":19389,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[13800,13801,13802,7559,13803,1128,13804,4184,127,505,13805,13799,13806,33,321],"class_list":["post-19388","post","type-post","status-publish","format-standard","has-post-thumbnail","category-samsung-biologics","tag-biomanufacturing","tag-capital-investment","tag-contract-development-and-manufacturing-organization-cdmo","tag-gsk","tag-human-genome-sciences","tag-manufacturing","tag-maryland","tag-rockville","tag-samsung","tag-samsung-biologics","tag-samsung-biologics-america","tag-samsung-biologics-maryland","tag-single-location","tag-south-korea","tag-supply-chain"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/19388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/comments?post=19388"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/posts\/19388\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media\/19389"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/media?parent=19388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/categories?post=19388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/korea\/wp-json\/wp\/v2\/tags?post=19388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}